|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC94 |
Gene summary for CCDC94 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC94 | Gene ID | 55702 |
| Gene name | YJU2 splicing factor homolog | |
| Gene Alias | CCDC94 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000349 | UniProtAcc | Q9BW85 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55702 | CCDC94 | P2T-E | Human | Esophagus | ESCC | 4.00e-12 | 1.34e-01 | 0.1177 |
| 55702 | CCDC94 | P4T-E | Human | Esophagus | ESCC | 3.45e-14 | 2.29e-01 | 0.1323 |
| 55702 | CCDC94 | P5T-E | Human | Esophagus | ESCC | 1.60e-08 | 6.31e-02 | 0.1327 |
| 55702 | CCDC94 | P8T-E | Human | Esophagus | ESCC | 2.59e-19 | 2.60e-01 | 0.0889 |
| 55702 | CCDC94 | P9T-E | Human | Esophagus | ESCC | 6.67e-21 | 3.08e-01 | 0.1131 |
| 55702 | CCDC94 | P10T-E | Human | Esophagus | ESCC | 2.70e-14 | 2.94e-01 | 0.116 |
| 55702 | CCDC94 | P11T-E | Human | Esophagus | ESCC | 5.20e-10 | 2.77e-01 | 0.1426 |
| 55702 | CCDC94 | P12T-E | Human | Esophagus | ESCC | 5.40e-16 | 3.01e-01 | 0.1122 |
| 55702 | CCDC94 | P15T-E | Human | Esophagus | ESCC | 1.10e-10 | 1.90e-01 | 0.1149 |
| 55702 | CCDC94 | P16T-E | Human | Esophagus | ESCC | 4.72e-13 | 1.03e-01 | 0.1153 |
| 55702 | CCDC94 | P17T-E | Human | Esophagus | ESCC | 2.62e-07 | 3.16e-01 | 0.1278 |
| 55702 | CCDC94 | P19T-E | Human | Esophagus | ESCC | 2.32e-02 | 2.15e-01 | 0.1662 |
| 55702 | CCDC94 | P20T-E | Human | Esophagus | ESCC | 1.28e-10 | 2.59e-01 | 0.1124 |
| 55702 | CCDC94 | P21T-E | Human | Esophagus | ESCC | 1.45e-13 | 1.29e-01 | 0.1617 |
| 55702 | CCDC94 | P22T-E | Human | Esophagus | ESCC | 1.20e-07 | 9.86e-02 | 0.1236 |
| 55702 | CCDC94 | P23T-E | Human | Esophagus | ESCC | 4.50e-28 | 5.79e-01 | 0.108 |
| 55702 | CCDC94 | P24T-E | Human | Esophagus | ESCC | 2.97e-14 | 1.46e-01 | 0.1287 |
| 55702 | CCDC94 | P26T-E | Human | Esophagus | ESCC | 1.12e-21 | 3.56e-01 | 0.1276 |
| 55702 | CCDC94 | P27T-E | Human | Esophagus | ESCC | 7.61e-18 | 2.37e-01 | 0.1055 |
| 55702 | CCDC94 | P28T-E | Human | Esophagus | ESCC | 4.06e-19 | 2.95e-01 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC94 | insertion | Nonsense_Mutation | novel | c.23_24insGTAGTAGTGTGT | p.Asn8delinsLysTerTerCysVal | p.N8delinsK**CV | Q9BW85 | protein_coding | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CCDC94 | insertion | Frame_Shift_Ins | novel | c.24_24+1insCTCCTAGGCATTTGTAAGACGTTTTCTCAATT | p.Lys9LeufsTer38 | p.K9Lfs*38 | Q9BW85 | protein_coding | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CCDC94 | SNV | Missense_Mutation | c.694G>A | p.Ala232Thr | p.A232T | Q9BW85 | protein_coding | tolerated(0.58) | benign(0.37) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC94 | deletion | In_Frame_Del | novel | c.642_644delGGA | p.Glu214del | p.E214del | Q9BW85 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCDC94 | SNV | Missense_Mutation | rs750361560 | c.134N>T | p.Thr45Met | p.T45M | Q9BW85 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC94 | SNV | Missense_Mutation | novel | c.770N>T | p.Arg257Leu | p.R257L | Q9BW85 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-EI-6513-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| CCDC94 | SNV | Missense_Mutation | c.175N>T | p.Arg59Trp | p.R59W | Q9BW85 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC94 | SNV | Missense_Mutation | c.725G>T | p.Arg242Met | p.R242M | Q9BW85 | protein_coding | deleterious(0.03) | benign(0.406) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC94 | SNV | Missense_Mutation | novel | c.460N>A | p.Leu154Ile | p.L154I | Q9BW85 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| CCDC94 | SNV | Missense_Mutation | c.16G>A | p.Val6Ile | p.V6I | Q9BW85 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |